Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: A cross-sectional study

Journal of International Medical Research

Volumn 32, Issue 1, 2004, Pages 70-77

  Gunal, A I ^a   Karaca, I ^a   Aygen, B ^a   Yavuzkir, M ^a   Dogukan, A ^a   Celiker, H ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Anti hypertensive drugs; Echocardiography; Haemodialysis; Left ventricular hypertrophy; Strict fluid volume control

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMODIALYSIS FLUID; NITRENDIPINE; PERINDOPRIL; RECOMBINANT ERYTHROPOIETIN; VASODILATOR AGENT;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FLUID BALANCE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART VENTRICLE SEPTUM; HEMODIALYSIS; HUMAN; HYPERVOLEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RENOVASCULAR HYPERTENSION; SODIUM RESTRICTION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WEIGHT GAIN;

EID: 0742289936     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000403200112     Document Type: Article

References (19)

1. Valderrabano F, Jones EP, Mallick NP: Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 (Suppl 5): 1 - 25.
2. Agodoa LY, Eggers PW: Renal replacement therapy in the United States: data from the United States Renal Data System. Am J Kidney Dis 1995; 25: 119 - 133.
3. Amann K, Ritz E: Reduced cardiac ischaemia tolerance in uraemia - what is the role of structural abnormalities of the heart? Nephrol Dial Transplant 1996; 11: 1238 - 1241.
4. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286 - 290.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186 - 192.
6. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, et al: The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 1990; 55: 114 - 120.
7. Ozkahya M, Ok E, Cirit M, Aydin S, Akcicek F, Basci A, et al: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13: 1489 - 1493.
8. Dorhout Mees EJ: Cardiovascular Aspects of Dialysis Treatment. Dordrecht: Kluwer Academic, 2000.
9. Hornett JD, Kent GM, Barre PE, Taylor R, Parfrey PS: Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4: 1486 - 1490.
10. Mailloux LU, Haley WE: Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998; 32: 705 - 719.
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072 - 1083.
12. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48 - 54.
13. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881 - 886.
14. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786 - 2796.
15. Chan CT, Floras JS, Miller JA, Richardson RMA, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235 - 2239.
16. Fagugli RM, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B, et al: Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001; 38: 371 - 376.
17. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, et al: Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987; 31: 973 - 980.
18. Sikole A, Polenakovic M, Spiroska V, Polenakovic B, Klinkmann H, Scigalla P: Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy. Artif Organs 2002; 26: 98 - 102.
19. London GM: Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17 (Suppl 1): 29 - 36.